Bipolar disorder (BD) is associated with higher body mass index (BMI) and increased metabolic comorbidity. Considering the associated phenotypic traits in genetic studies of complex diseases, either by adjusting for covariates or by investigating interactions between genetic variants and covariates, may help to uncover the missing heritability. However, obesity-related traits have not been incorporated in prior genome-wide analyses of BD as covariates or potential interacting factors. To investigate the genetic factors underlying BD while considering BMI, we conducted genome-wide analyses using data from the Genetic Association Information Network BD study. We analyzed 729 454 genotyped single-nucleotide polymorphism (SNP) markers on 388 EuropeanAmerican BD cases and 1020 healthy controls with available data for maximum BMI. We performed genome-wide association analyses of the genetic effects while accounting for the effect of maximum BMI, and also evaluated SNP-BMI interactions. A joint test of main and interaction effects demonstrated significant evidence of association at the genome-wide level with rs12772424 in an intron of TCF7L2 (P = 2.85E − 8). This SNP exhibited interaction effects, indicating that the bipolar susceptibility risk of this SNP is dependent on BMI. TCF7L2 codes for the transcription factor TCF/LF, part of the Wnt canonical pathway, and is one of the strongest genetic risk variants for type 2 diabetes (T2D). This is consistent with BD pathophysiology, as the Wnt pathway has crucial implications in neurodevelopment, neurogenesis and neuroplasticity, and is involved in the mechanisms of action of BD and depression treatments. We hypothesize that genetic risk for BD is BMI dependent, possibly related to common genetic risk with T2D.
INTRODUCTION
Bipolar disorder (BD) has a high heritability estimated between 60% and 85%. 1, 2 To identify common genetic risk factors for BD, multiple genome-wide association (GWA) studies have been conducted. Although allele risk variants have been identified in various genes, including ANK3, CACNA1C and ODZ4, [3] [4] [5] [6] these variants vary widely between studies and explain a very limited proportion of the heritability of BD.
Complex phenotypes, including psychiatric disorders like BD, are hypothesized to involve a large number of environmental and genetic components interacting to confer illness. In addition, they might share genetic risk variants with other phenotypic traits. 7 Hence, models involving relevant phenotypic traits as covariates and interacting risk factors should be considered in the search for genetic factors contributing to complex phenotypes.
In particular, BD is positively associated with many phenotypic traits, including obesity (usually defined as body mass index (BMI) ⩾30 kg/m 2 ) and therefore higher BMI, with one cross-sectional study showing an obesity rate of 41% in BD compared with 27% in those without BD. 8 This comorbidity has strong clinical implications as several studies have shown that bipolar patients with comorbid obesity have a higher psychiatric and general illness burden and increased mood-episode recurrence. [9] [10] [11] [12] For example, we found greater rates of binge eating, higher degrees of suicidality and greater general medical burden in subjects with BD and higher BMI, 12 indicating that this phenotype defines a clinically important subgroup. Furthermore, BMI is a heritable complex trait 13 that is also associated with other psychiatric disorders including schizophrenia, major depressive disorder and binge eating disorder, 14, 15 motivating the inclusion of BMI in the investigation of genetic risk factors for metabolic and psychiatric phenotypes.
The positive association between BD and BMI (as a measure of obesity), together with the heritability of both BD and BMI, suggests a potential interaction in the genetic mechanisms underlying those traits. In prior GWA studies of type 2 diabetes (T2D) and insulin resistance, accounting for differences in BMI resistance. 18 By accounting for BMI effects, these studies found significant risk loci. In analyses of T2D in the Wellcome Trust Case Control Consortium cohort stratified by obesity status, Timpson et al. 16 identified a variant in TCF7L2-a known, strong T2D susceptibility gene-not previously identified in the full cohort. In addition, Manning et al. examined SNP effects on fasting insulin while accounting for the effect of BMI as well as potential SNP-BMI interactions, and observed six novel genome-wide significant loci (P o 5E − 8) that were also associated with higher triglyceride and lower high-density lipoprotein cholesterol levels, suggesting involvement in insulin resistance pathways. 16, 17 Despite the known correlations between BD and obesity, BMI has not previously been incorporated in GWA studies of BD. Following a rationale similar to the one used in T2D research, we propose to reduce BD phenotypic heterogeneity by accounting for differences in BMI between BD patients and healthy individuals, as well as potential SNP-BMI interactions on BD disease susceptibility. Utilizing publicly available data from a previous GWA study carried out by the Genetic Association Information Network (GAIN), 4 we reevaluate genetic associations with BD while incorporating data on maximum lifetime BMI. In particular, we conducted GWA analyses adjusted for BMI and examined potential SNP-BMI interaction effects.
MATERIALS AND METHODS

Study description
The Bipolar Disorder Genome Study Consortium (BiGS) conducted a GWA study of BD; the data is available as part of the GAIN BP data in dbGaP 19 and has been previously described by Smith et al, 4 including descriptions of study subjects and genotyping and quality control procedures. Although the BiGS/GAIN study included data from both EuropeanAmerican (EA; N = 2035) and African-American (AA; N = 1015) subjects, we restricted our analyses to the EA subjects to avoid population stratification.
Over the 18-year recruitment period, 1001 BD subjects were enrolled at multiple institutions. All cases met the criteria for DSM IV-defined bipolar I disorder. However, subjects recruited at different times were interviewed with either the Diagnostic Interview for Genetic Studies 2, 3, or 4 (DIGS 2, 3, 4). Current height (inches) and maximum lifetime body weight (pounds) were collected only in DIGS 4, and therefore self-reported maximum BMI (max BMI) was available only in a subset of 388 of the EA cases. Current body weight and other weight measures in addition to lifetime maximum body weight were not available.
Control subjects completed a separate psychiatric questionnaire, and were excluded if they met diagnostic criteria for depression or had a history of BD or psychosis. Controls were matched to cases for both gender and ethnicity. 4 Current height and maximum lifetime body weight were collected in the control questionnaire, and self-reported max BMI data were available for 1020 of the EA controls.
Statistical analysis
We conducted GWA analyses of 729 454 SNP markers on the 388 EA bipolar cases and 1020 EA mentally healthy control subjects with available BMI data. GWA analyses were conducted by comparing cases with controls to evaluate the genetic association with BD while allowing for the possibility that this effect may be modified by max BMI. For each SNP, we fit a logistic regression model including the SNP effect (assuming a logadditive genetic model), max BMI and the SNPxBMI interaction. To evaluate the genetic effect of each SNP, we conducted a joint two-degreeof-freedom likelihood ratio test involving both the marginal SNP effect and the SNPxBMI interaction. 20 The joint two-degree-of-freedom test has been shown to be a powerful method to detect genetic associations because it allows for either a marginal or interaction effect. However, the joint test does not characterize the nature of this association. Therefore we also performed genome-wide analyses of the marginal genetic effect adjusted for the effect of BMI, and the SNP-BMI interaction effect separately. To evaluate the SNP-BMI interaction effect, we conducted a one-degree-offreedom test of the interaction effect in the logistic regression model. To examine the marginal genetic effect after adjusting for max BMI, we fit a logistic regression model including only the log-additive SNP effect and max BMI, and conducted a one-degree-of-freedom test of the SNP effect.
As previously mentioned, the analyses were restricted to the EA sample to avoid confounding by population structure. Moreover, we employed principle components analysis as a safeguard to further correct for population stratification. 21 We evaluated the top four principle components (PCs), and determined that none were associated with either BD or max BMI (P>0.5). Therefore, the reported analyses are not adjusted for PCs. QQ plots were used to measure the degree of inflation of association statistics, and sensitivity analyses were conducted correcting the top genome-wide associations for the first PC.
All analyses were performed in R Statistical Software, version 2.14.0 (http://www.r-project.org/). We used a genome-wide statistical significance threshold of Po5E − 8.
Network analysis
Following GWA analyses, we implemented Ingenuity Pathway Analysis (IPA) using SNP P-values from the two degree-of-freedom tests to aid in the interpretation of the results (www.ingenuity.com). SNPs were assigned to genes within 10 kb using NCBI Build 37, and were pre-filtered to P ⩽ 0.05; this resulted in over 11 000 top SNPs mapped to genes considered for network and pathway analysis.
With the use of a functional analysis algorithm, IPA constructed networks of direct and indirect interactions between genes and molecules in our data on the basis of published, peer-reviewed literature within the curated Ingenuity Knowledge Base. In addition, IPA was used to identify gene sets with enriched association signals, among gene sets representing predefined processes of biological functions, disease states and canonical pathways. Gene set enrichment was tested using a 2 × 2 contingency righttailed Fisher's exact test applied to counts of genes with P-values o 0.001, where gene P-values were defined by the minimum P-value for SNPs mapping to the gene.
Genome-wide imputation
Analyses were repeated with imputed SNP data. Haplotype phasing was performed with SHAPEIT, 22 and genome-wide imputation was conducted on the phased data using Impute 2.2.2, 23 using the 1000 Genomes Phase 1 data as the reference panel (all populations). SNPs with poor imputation quality (dosage R 2 o 0.3) or low minor allele frequency (o 0.01) were removed, leaving 8 466 825 SNPs for analysis.
RESULTS
BD cases had a significantly higher max BMI than controls (median of 31.3 vs 29.3 kg/m 2 ; P = 3.96E − 6 from Wilcoxon test). In the two-degree-of-freedom GWA analysis that tested the SNP effects while incorporating possible SNP-BMI interaction effects, the top ranking variant was rs12772424 in an intron of TCF7L2, which achieved statistical significance at the genome-wide level (P = 2.85E − 8, Table 1 , Figure 1c ). Further investigation of the main and interaction effects shows a significant interaction between BMI and this SNP, where the minor allele has a stronger protective effect as BMI decreases (Figure 1b) .
Other top association signals included rs17541406 in the pseudogene SEPHS1P2, downstream of MCTP2 (P = 1.21E − 6), with the same pattern of genetic effect that is dependent on BMI. Variants in the protein-coding regions of WW domain-containing oxidoreductase (WWOX)(rs11150078, P = 1.73E − 6) and CDH23 (rs1625975, P = 4.16E − 6) were also highly ranked and demonstrated evidence of interaction effects (Table 1, Figures 1b and c) .
The minor allele of rs7690204, in a protein-coding region of GYPA, exhibited a marginal protective effect (odds ratio = 0.65, P = 1.11E − 6; Table 1, Figure 1a) but not of a SNP-BMI interaction. Similarly, two SNPs residing in an intergenic region upstream of MARCKS, rs6934970 and rs17074473 (in linkage disequilibrium), are also highly ranked (P = 7.08E − 6 and P = 8.23E − 6, respectively; Figure 1c ) in the analysis of marginal genetic effect after adjusting for BMI, but showed no evidence of an interaction with BMI. Specifically, the minor allele of rs6934970 is associated with an increased odds of BD after accounting for BMI (odds ratio = 1.83, P = 8.5E − 7; Table 1, Figure 1a) .
The association test statistics in the GWA analyses were not strongly inflated (λ = 1.04 for the two-degree-of-freedom test allowing for a BMI-SNP interaction), suggesting no substantial population stratification. There is little change in the results after adjusting for the first PC, although the effect sizes of some SNPs are attenuated (Supplementary Table 1 ). The QQ plots for the unadjusted and PC-adjusted analyses are shown in Supplementary Material (S1 and S2).
The highest ranked canonical pathways based on IPA included 'synaptic long-term depression', 'G-protein αq signaling', and 'synaptic long-term potentiation' ( Table 2) . Top networks include molecules involved in cellular growth and development, as well as cardiovascular system development and signaling (Figure 2) .
Imputed results were similar to the results for the observed genotypes, with denser peaks in the top ranking regions (Supplementary Figure S3 shows the results for the two-degreeof-freedom analysis). In the two-degree-of-freedom analysis of Table 2 ). This peak is in an intergenic region downstream of TRIM42, and includes SNPs rs72977016, rs182827559 and rs60035994, all of which represent rare variation (minor allele frequency o0.01). Because the minor allele frequencies of these SNPs are low, and thus imputation quality is poor, this new peak should be interpreted with caution.
SNP effect including BMI-SNP interaction, a new peak was observed on chromosome 3 (Supplementary
DISCUSSION
Recognizing the relationship between BD and BMI, in the current study we used a genome-wide approach to identify novel BDsusceptible SNP variants after accounting for the association of lifetime max BMI with BD; furthermore, we also allowed SNP effects on BD risk to depend on BMI (i.e., SNP-BMI interaction effects). Most prior genome-wide analyses for BD have implemented univariate, one-SNP-at-a-time analyses, overlooking complex models including relevant covariates and interactionscritical factors for complex traits. The reduction of variation and confounding effects through covariate adjustment and incorporation of interactions was central to the current study.
By investigating max BMI as an interacting factor, we were able to detect novel genetic variants correlated with susceptibility to BD. Our top SNP resides in a gene of biological plausibility for both BD-and BMI-related phenotypic traits, which may be an important component in the biological mechanisms linking BD and its metabolic impact. We observed strong evidence of a SNP-BMI interaction involving a variant in TCF7L2 at the genome-wide level. When the associations between rs12772424 and BD or BMI are analyzed separately, there is no evidence for a marginal SNP effect on either trait; yet when examined collectively, we observe a SNP-BMI interaction on BD risk where the protective effect of the minor allele becomes stronger as BMI decreases.
TCF7L2 is the strongest genetic risk factor for T2D [24] [25] [26] and notably, a risk locus of T2D in a study stratifying subjects by BMI.
16 TCF7L2 codes a T-cell factor/lymphoid enhancer factor, that upon β-catenin translocation to the nucleus activates the expression of target genes downstream of the Wnt/β-catenin canonical pathway. 27, 28 This signaling transduction cascade has Figure 2 . BMI-gene interaction network implicated in BD disease risk. Highest scoring network including many of the genes from the 'Cellular Growth and Proliferation, Cardiovascular System Development and Function, Organismal Development' canonical pathway and fourth highest scoring network including many of the genes from the 'Cellular Development, Cellular Growth and Proliferation, Skeletal and Muscular System Development and Function' canonical pathway are shown together to illustrate the interaction between top genes in our analysis. The color of the genes indicates the degree of association in our analyses: red = lowest P-value, pink = low/moderate P-value, gray = moderate P-value and white = P>0.001. Shapes indicate the gene/molecule type (cytokine, transporter, kinase, so on). Solid lines indicate direct relationships and dashed lines indicate indirect relationships. Note: Wnt, Wnt receptor frizzled, co-receptor LPR1, cytoplasmic signal transduction protein disheveled, and B-catenin destruction complex components, AXIN1 and APC, were added to the network to illustrate the Wnt canonical pathway upstream of genes CTNNB1, GSK3B and TCF7L2 shown in our analysis. been linked to many diseases-most notably cancer-and is critically involved in the development of many organisms, including humans. 29 The Wnt/β-catenin canonical pathway is crucial to different aspects of neuroplasticity 30 and adult neurogenesis. [31] [32] [33] The action of mood stabilizers on this signaling pathway is regarded as indirect evidence of its involvement in BD pathophysiology. 34 Lithium antidepressant effects on behavior, for example, have been hypothesized to be secondary to inhibition of the β-catenin inactivator GSK-3β 35, 36 through direct 37, 38 and indirect mechanisms 39 ; β-catenin has similar effects to lithium in rodent models. 40 Valproate has also been suggested to inhibit GSK-3β and additionally to increase mRNA Wnt/β-catenin canonical pathway targets in the hippocampus. 41 Recently, neurons differentiated from induced pluripotent stem cells of schizophrenic patients have shown altered expression of many components in this pathway, including different TCF/LF isoforms. 42 Furthermore, multiple animal findings have associated several steps of this cascade to stress induced depressive and antidepressant response. 43 TCF/LF involvement in both neuropsychiatric disorders and T2D makes it a feasible candidate for complex shared genetic risk.
Moreover, the variant rs1625975 in CDH23, part of the cadherin superfamily of cell-cell adhesion glycoproteins, was highly ranked in our analysis. Several cadherins have been shown to suppress β-catenin activity, 44 and hence are negatively regulated by Wnt signaling. 45 Also, several cadherin and adhesion glycoproteincoding genes have previously been associated with BD in genetic studies. [46] [47] [48] [49] [50] Rs11150078 in WWOX presented an inverse relationship to that observed with TCF7L2, suggesting a protective effect of the minor allele on BD risk as BMI increases. The WWOX gene codes a protein that sequesters transcription factors involved in neoplasias, 51 and defects have been widely studied in cancer literature. WWOX interacts with multiple signaling pathways including Wnt, 52 but to our knowledge has not been previously related to psychiatric disorders.
IPA network analysis defined an interactome that links two of our top genes, TCF7L2 and WWOX, together and emphasized additional genes of potential relevance via interaction with β-catenin promoters Jun and Rap1 and inhibitor GSK-3β: growth factor downstream signaling cascade molecules Akt and Erk (Figure 2 ). Furthermore, an enriched 'cell death and survival' network involves BD risk genes CACNA1C, 6 CACNA2D1 and CACNB3.
This study incorporated additional information on max BMI into the genome-wide analyses of BD risk, identifying novel genetic variants with biological relevance. Interestingly, we observed genetic associations with greater statistical significance than the original analyses, despite the fact that our analyses were restricted to those with available max BMI data (i.e., 388 cases/1020 controls vs 1001 cases/1034 controls). These results suggest that we attained higher power to detect genetic effects through the reduction of heterogeneity due to integration of a crucial covariate. In general, the top ranking SNPs in our analyses were quite different from those reported for European Americans in Smith et al. 4 Many of the estimated odds ratios for the previously reported top SNPs are attenuated in our analyses, indicating that BMI may be a confounding factor (Table 3) . However, rs7690204 in GYPA was highly ranked in both studies. In fact, both rs7690204 and rs10193871 in NCKAP5 (a.k.a. NAP5) demonstrated stronger protective effects in our analyses accounting for BMI (Table 3) .
Although there are clear advantages of our approach to identify genetic risk factors by integrating relevant covariates and interacting factors into analyses, there are also limitations. In the study from which the data were drawn, subsets of bipolar cases received diagnostic interviews based on different versions of DIGS. Only subjects who were interviewed with DIGS 4 were asked their current height and maximum lifetime weight, which restricted our analyses to only those subjects, limiting the available sample size and effectively reducing power; yet even with a small sample size, phenotypic heterogeneity was reduced through the inclusion of BMI, and we were able to uncover novel genetic associations of genome-wide significance. Furthermore, the lifetime maximum weight used in the analyses was based on self-report, which may underestimate BMI and potentially bias results. Finally, other measures of BMI (such as current BMI) were not available in this sample, limiting the scope of our conclusions to the lifetime measure of max BMI and hindering comparisons to the general population. However, as opposed to current BMI, lifetime BMI may be more relevant with regard to obesity and cardiovascular comorbidities, and may be a more relevant phenotype for genetic association studies.
It is important to recognize that BMI may represent a more intermediary measure related to other underlying conditions. For instance, many of the most effective medications to treat BD, such as neuroleptics, are associated with weight gain. Our analyses do not account for the current treatment that each case was receiving or the weight gain that may have been associated with that treatment, and hence our results may be confounded with medication type or treatment response. Although basic information on lifetime antipsychotic use is available, detailed information about current medication usage, duration and dosage, treatment response and associated weight gain were not; rarely is such reliable information available in a retrospective study, making accounting for confounding effects of medication type or treatment response challenging. Nevertheless, an examination of the impact of medication use and treatment-associated weight gain on the associations observed here is an important area of future research.
Furthermore, in this study, we did not have data on T2D history and thus could not investigate whether BMI may be a surrogate for T2D predisposition. In addition to T2D, high BMI is strongly associated with numerous diseases and disorders, including other psychiatric disorders and comorbidities (such as binge eating disorder), as well as metabolic disorders and heart disease, further complicating the interpretation of our results. Determining genetic factors correlated with BD and BMI is only the beginning in understanding the causal biological and genetic mechanisms. In fact, this study suggests a potential for shared genetic risk factors between psychiatric traits and metabolic disorders, such as BD and T2D, which have exhibited significant genetic overlap in previous network analyses. 7 Although not directly investigated here, a simultaneous examination of common genetic risk factors for multiple comorbidities-pleiotropic effects-could shed further light on the meaning behind the identified associations of this study. Follow-up cohort and functional studies are necessary to decipher the complexity of these associations and to understand the relationship between BMI and the genetic predisposition to BD.
To our knowledge, the current study is the first to investigate genome-wide genetic risk factors for BD and obesity-related measures simultaneously. In this study, we identified many biologically relevant genetic variants that are associated with BD, after accounting for the effect of max BMI. Further investigation is needed to replicate and validate these relationships and to determine if the identified variants or genes have a functional role in disease susceptibility. Investigating complex genetic relationships involving covariates and genetic interactions is necessary to better understand the genetic etiology of BD and obesity.
